Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-I109V in virally suppressed HBeAg-negative chronic hepatitis B
ACTRN12620000403932Phase 2Recruiting
- Sponsor
- Immunocore
- Start
- May 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of IMC-I109V in Chronic Hepatitis B (CHB) (2 arms), sponsored by Immunocore. Primary endpoints: Safety and tolerability of single-dose IMC-I109V and Safety and tolerability of multiple-dose IMC-I109V. Started May 2021; status: recruiting.
02
Drugs
IMC-I109V
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ACTRN12620000403932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000403932.